The mental state of patients is an important aspect that affects physical health and the quality of life. Mild Cognitive impairment (MCI) is associated with an increased risk of developing Alzheimer’s disease (AD). The recognition of this condition and the early identification of the underlying neurodegenerative processes are essential for planning the most successful treatment strategy. In this review, we discuss mild cognitive impairment and the different tools that have been implemented into the primary care setting. Over the years, different screening tools have been created and adapted to the medical setting to be used as a diagnostic entity. These tools have evolved with review and led to the invention of more concise and brief tests with adaptation to languages and other factors that could affect the individual. It is important to understand the benefits and the limitations of each test and advance from the previous versions by creating a better standardized version that is dependable and sensitive to diagnose the individual. Apart the screening tests, which is administered on paper and evaluated with scores, there also exists the biomarkers and structural neuroimages that can be used as a diagnostic possibility for understanding cognitive impairment, it’s etiologies and predilection causes. Though biomarkers open the possibilities for improved and advanced diagnostic answers, it is scrutinized and not appropriately adapted to the clinical setting. The reasons for this are discussed further in this paper. The correct, confirmed diagnosis requires multiple tools that need to be executed properly. These tools should have the right practical application and efficacy so that we reach not only the accurate diagnosis but also can come to the right management plan for the patient to not progress into severe cognitive impairment.